Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events

Nature Clinical Practice Cardiovascular Medicine

Volumn 6, Issue 3, 2009, Pages 229-239

  Jaeger, Beate R ^a   Richter, Yvonne ^b   Nagel, Dorothea ^b   Heigl, Franz ^c   Vogt, Anja ^d   Roeseler, Eberhard ^e   Parhofer, Klaus ^f   Ramlow, Wolfgang ^c   Koch, Michael ^g   Utermann, Gerd ^h   Labarrere, Carlos A ⁱ   Seidel, Dietrich ^b  

^a MVLMIVTH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Medizinisches Versorgungszentrum Kempten Allgäu ^*  (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Klinik für Nieren und Hochdruckkrankheiten Hannover   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g Dialysepraxis Ardeystrasse   (Germany)

^h UNIVERSITY OF INNSBRUCK   (Austria)

ⁱ METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; NICOTINIC ACID; NITRATE; OMEGA 3 FATTY ACID; PHENPROCOUMON;

ADOLESCENT; ADULT; AGED; APHERESIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERLIPOPROTEINEMIA; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY PREVENTION; PRIORITY JOURNAL; THERAPY EFFECT; THROMBOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTILIPEMIC AGENTS; BLOOD COMPONENT REMOVAL; COHORT STUDIES; COMBINED MODALITY THERAPY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LIPOPROTEIN(A); LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 61549101898     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1456     Document Type: Article

References (40)

1. Berg K (1963) A new serum type system in man: The Lp system. Acta Pathol Microbiol Scand 59: 369-382
2. Rifai N et al. (2004) Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians Health Study. Clin Chem 50: 1364-1371
3. Bostom AG et al. (1996) Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 276: 544-548
4. Berg K et al. (1997) Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival study. Clin Genet 52: 254-261
5. Kronenberg F et al. (1999) Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis. Results from the Bruneck study. Circulation 10: 1154-1160
6. Kostner GM et al. (1981) Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 38: 51-61
7. Cremer P et al. (1994) Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL-cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 24: 444-453
8. Danesh J et al. (2000) Lipoprotein(a) and coronary heart disease, meta-analysis of prospective studies. Circulation 102: 1082-1085
9. Luc G et al. (2002) Lipoprotein(a) as a predictor of coronary heart disease: The PRIME study. Atherosclerosis 163: 377-384
10. Utermann G (1989) The mysteries of lipoprotein(a). Science 346 904-910
11. Bennett A et al. (2008) Lipoprotein(a) levels and risk of future coronary heart disease. Large-scale prospective data. Arch Intern Med 168: 598-608
12. Hajjar KA and Nachman R (1996) The role of lipoprotein(a) in atherogenesis and thrombosis. Annu Rev Med 47: 423-442
13. Strater R et al. (2002) Prospective assessment of risk factors for recurrent stroke during childhood: A 5-year follow-up study. Lancet 360: 1540-1545
14. Dieplinger B et al. (2007) Increased serum lipoprotein(a) concentrations and low molecular weight phenotypes of apolipoprotein(a) are associated with symptomatic peripheral arterial disease. Clin Chem 53: 1298-1305
15. von Eckardstein A et al. (2001) Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 37: 434-439
16. Panza F et al. (2007) Lipoproteins, vascular-related genetic factors, and human longevity. Rejuvenation Res 10: 441-458
17. Thompson GR et al. (1995) The familial hypercholesterolaemia regression study: A randomised trial of low-density-lipoprotein apheresis. Lancet 345: 811-816
18. Kroon AA et al. (1996) LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 93: 1826-1835
19. Maher VM et al. (1995) Effects of lowering elevated LDL cholesterol on the cardiovascular risk of Lp(a). JAMA 274: 1771-1774
20. Kraft HG et al. (1996) Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 16: 713-719
21. Sandholzer C et al. (1992) Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb 12: 1214-1226
22. Marcovina SM et al. (2003) Report of the National Heart, Lung and Blood Institute on lipoprotein(a) and cardiovascular disease: Recent advances and future directions. Clin Chem 49: 1785-1796
23. Kostner GM et al. (1993) Preparation of a stable fresh frozen primary lipoprotein[a] (Lp[a]) standard. J Lipid Res 40: 2255-2263
24. Kronenberg F et al. (2004) Lipoprotein(a)- and low-density- derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy? Kidney Int 66: 348-354
25. Kamstrup PR et al. (2008) Extreme lipoprotein(a) levels and the risk of myocardial infarction in the general population: The Copenhagen City Heart Study. Circulation 117: 176-184.
26. Brown BG et al. (2001) Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345: 1583-1592
27. Derosa G et al. (2007) Effects of nateglinide and glibenclamide on prothrombotic factors in native type 2 diabetic patients treated with metformin: A 1-year, double-blind, randomized clinical trial. Intern Med 46: 1837-1846
28. Danik JS et al. (2008) Lipoprotein (a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol 52: 124-131
29. Straube R and Kingreen H (1998) Lipoprotein(a)-immunapheresis in the treatment of familiar lipoprotein(a) hyperlipoproteinemia in a patient with coronary heart disease. Ther Apher 2: 243-245
30. Daida GH et al. (1994) Prevention of restenosis after percutaneous transluminal angioplasty by reducing lipoprotein(a) levels with low-density lipoprotein apheresis. Low-Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) group. Am J Cardiol 73: 1037-1040
31. Jaeger BR (2003) The HELP system for the treatment of atherothrombotic disorders: A review. Ther Apher Dial 7: 391-396
32. Beschluss des Bundesausschusses der Ärzte und Krankenkassen vom 24.03.2003 (BUB-Richtlinien). (Reimbursement guidelines of the indication for chronic lipid apheresis by the German Federal Joint Committee as of March 24, 2003.) Dtsch Ärztebl 8: 373-374
33. Cummins RO et al. (1991) Recommended guidelines for uniform reporting of data from out-of-hospital cardiac arrest: The Ulstein-style: A statement for health professionals from a task force of the American Heart Association, the European Resuscitation Council, the Heart and Stroke Foundation of Canada, and the Australian Resuscitation Council. Circulation 84: 960-975
34. Smith SC Jr et al. (2006) AHA/ACC Guidelines for secondary prevention for patients with coronary or other atherosclerotic vascular disease: 2006 update. J Am Coll Cardiol 47: 2130-2139
35. European Patent by Dietrich Seidel: International publication number: WO_2001/048476 (05.07.2001, Gazette 2001/27), International registration number: PCT/EP/00/13294 published 9th March 2005, Patentblatt 2001/1 (EP1 242 825 B1)
36. Bosch T (1996) State of the art of lipid apheresis. Artif Organs 20: 292-295
37. Mikrozensus 2005: Fragen zur Gesundheit, Statistisches Bundesamt 2006; chapter: Rauchgewohnheiten der Patienten, page 13. Article number: 5239004059004.
38. Desmarais RL et al. (1995) Elevated lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 91: 1403-1409
39. Cushing GL et al. (1989) Quantification and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis 99: 593-603
40. Barre DE (2007) The molecular nature and consequences of lipoprotein (a)'s association with platelets. Protein Pept Lett 14: 839-842